Cardiovascular disease in people with HIV

• Research type

  Research Study

• Full title

  Biomarkers, clinical characteristics and imaging: current and new tools to diagnose and manage cardiovascular disease in people with HIV.

• IRAS ID

  347635

• Contact name

  Marta Boffito

• Contact email

  marta.boffito@nhs.net

• Sponsor organisation

  Chelsea and Westminster Hospital R& D

• Duration of Study in the UK

  1 years, 11 months, 2 days

• Research summary

  With early treatment and appropriate care people with HIV(PWH) can expect to live as long as their peers who do not have HIV. Despite the best treatment, PWH are at a higher risk of coronary artery disease(CAD) and heart failure than the general population.
  
  Heart failure is the inability of the heart to pump blood around the body sufficiently. It can happen for many different reasons with the most common being the aftermath of a heart attack.
  
  BNP is a hormone produced by the body when the heart is enlarged. Therefore, in patients with heart failure, it may be raised. NT- proBNP is a product of BNP and research suggests it is a better test at identifying all patients with heart failure
  
  In PWH a possible explanation as to why CAD and cardiomyopathy are more common is chronic inflammation which puts the body’s tissue under stress causing long term cell damage, contributes to the narrowing of vessels and can affect the heart muscle itself.

  A specialist HIV/Cardiology clinic was thus created to review patient's at increased risk; those at higher risk undergo calcium scans and MRI scans of their heart. We will assess whether individuals have CAD, heart failure or cardiomyopathy. We will look at their notes to see if they had a NT-proBNP checked. Information about their general health, other medical issues, medications and social history will also be collected. PWH will be asked to provide a blood sample for special blood markers to assess if there is a relationship between these and CAD, heart failure and cardiomyopathy.

  Our goal is to be able to work out which PWH are at a higher risk of heart disease using markers such blood markers such as NT- proBNP and other factors such as their general health, medical problems to help predict this.
  

• REC name

  London - Camden & Kings Cross Research Ethics Committee

• REC reference

  24/LO/0707

• Date of REC Opinion

  26 Nov 2024

• REC opinion

  Further Information Favourable Opinion